- Report
- October 2024
- 183 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- April 2023
- 110 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- March 2024
- 200 Pages
Global
From €3940EUR$4,150USD£3,323GBP
- Report
- March 2025
- 50 Pages
Global
From €2516EUR$2,650USD£2,122GBP
- Report
- March 2025
- 50 Pages
Global
From €2516EUR$2,650USD£2,122GBP
Clofibrate is a type of cardiovascular drug used to reduce cholesterol levels in the blood. It works by inhibiting the activity of an enzyme called lipoprotein lipase, which is responsible for breaking down fats in the blood. Clofibrate is usually prescribed to people with high cholesterol levels, as it can help reduce the risk of heart disease and stroke. It is also used to treat certain types of gallstones.
Clofibrate is available in both generic and brand-name forms. Common brand names include Atromid-S, Lofibra, and Lipocamb. It is usually taken orally, either as a tablet or capsule, and is available in different strengths.
The clofibrate market is highly competitive, with many companies offering different formulations of the drug. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more